Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)

Oct 17, 2022

–AD109 Achieved the Primary Endpoint of Reduced Nighttime Airway Obstruction –AD109 Significantly Improved Daytime Impairment Caused by OSA –AD109 Was Well-Tolerated CAMBRIDGE, Mass. October 17, 2022 – Apnimed, a clinical-stage pharmaceutical company...

Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1×1 Forum

Oct 12, 2022

CAMBRIDGE, Mass October 12, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that company...

Canaccord Genuity Virtual 41st Annual Growth Conference

Aug 13, 2021

Thursday, August 12th at 4:00pm EDT   News 2020 2021 2022 Events Past...

Ladenburg Thalmann Virtual Healthcare Conference

Jul 6, 2021

Tuesday, July 13th at 1:30 pm ET   News 2020 2021 2022 Events Past...

Apnimed to Present at the Ladenburg Thalmann Virtual Healthcare Conference

Jul 6, 2021

CAMBRIDGE, Mass. July 6, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Ladenburg...